LONDON, March 22, 2012: On the third and final day of BIO-Europe Spring® 2012 this week, Index Ventures announced the launch of its first fund solely dedicated to making investments in the life sciences sector. This €150m fund includes investments from several of Index's largest existing limited partners and two companies, GlaxoSmithKline (GSK) and the venture capital affiliate of the Janssen pharmaceutical companies of Johnson & Johnson (Janssen). Morgan Lewis served as legal advisor to GSK on the transaction.
The Morgan Lewis team was led by Private Investment Funds partner Peter Phleger, and included partners Randall Sunberg (Business & Finance), Kate Habershon (Tax), and associate Jarrod Huffman (Tax).